Previous 10 | Next 10 |
Adamas Pharmaceuticals ( ADMS ) has taken numerous steps to proliferate GOCOVRI adoption and the numbers are slowly grinding higher. The company’s third-quarter product sales came in a $13.9M, which was a 9% increase over Q2 and a 31% increase over Q3 of last year. Thus far, GOCOVRI h...
The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with this Read more ...
Gainers: HQY +11.9% . RAPT +8.2% . CIH +8.2% . SIGA +5.0% . NPO +4.8% . More news on: HealthEquity, Inc., RAPT Therapeutics, Inc., China Index Holdings Limited, Stocks on the move, Read more ...
EMERYVILLE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive...
Adamas Pharmaceuticals, Inc. (ADMS) Q3 2019 Earnings Conference Call November 07, 2019, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Neil McFarlane - CEO & Director Vijay Shreedhar - Chief Commercial Officer Rajiv Patni - Chief Medical Officer Christophe...
The following healthcare companies have file for mixed shelf offerings: More news on: Adamas Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Adamas Pharma (NASDAQ: ADMS ): Q3 GAAP EPS of -$0.99 misses by $0.11 . Revenue of $13.9M (+31.0% Y/Y) misses by $0.17M . Shares -4.3% . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640 - Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019 EMERYV...
EMERYVILLE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas’ management team will host a con...
Noteworthy events during the week of October 27 - November 2 for healthcare investors. More news on: AMAG Pharmaceuticals, Inc., Agile Therapeutics, Inc., Adamas Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...